Anti-HRV-A16 VPg di-uridylylated antibody (anti–VPg-pU(pU))
Anti-HRVA16 VPg di-uridylylated antibody (anti–VPg-pU(pU)) raised against the N-terminal of the VPg peptide in the di-uridylylated form. VPg is crucial for Human rhinovirus (HRV) polymerisation.
Catalogue number crb2005637 Antibody Anti-HRV-A16 VPg di-uridylylated antibody (anti–VPg-pU(pU)) Antigen Peptide KLH conjugated synthetic peptide crb1200844 Aliases VPg Cross-Reactivity human rhinovirus (HRV) Target Protein Species human rhinovirus (HRV) Host Species Anti-Rabbit Antibody Type Polyclonal Concentration 0.5 mg/ml (R1G) 0.2 mg/ml (R2G) Validation ELISA (1:1000) Target HRVA16 di-uridylated Storage Stabilisers The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Disease Area Asthma, COPD Specificity Protein Post-translational Modification Uridylation Storage The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Citations
Gingras R, Mekhssian K, Fenwick C, White PW, Thibeault D. (2104). Human rhinovirus VPg uridylylation AlphaScreen for high-throughput screening. J Biomol Screen. Feb;19(2):259-69. PMID: 23813021.
Human rhinoviruses (HRV) are the leading cause of the common cold, asthma, and chronic obstructive pulmonary disease exacerbations. This has led to the search for therapies that inhibit the HRV-induced inflammatory response or prevent viral infectivity. There is significant genetic diversity in the HRV family hence a lack of natural immunity, which also hampers the development of vaccines; HRV genetic diversity also is the reason there are no available broad-spectrum antivirals with direct action on HRV. A putative strategy is the identification of rhinovirus replication inhibitors targeting the polymerase activity. An initial step in HRV replication is the conjugation of viral peptide VPg uridine nucleotides to substrates, which serve as the primer for polymerisation. An antibody was raised against virus HRV-A16 peptide VPg N-terminal (GPYSGEPKPK) in the di-uridylylated form. The HRVA16 di-uridylylated antibody was crucial. It has been possible to reconstitute the uridylylation reaction to allow high-throughput screening and use the HRV-A16 VPg di-uridylylated antibody in the assay to identify novel inhibitors of human rhinovirus (HRV) VPg uridylylation with potential uses in the future as clinical antiviral drugs.